Specialty Pharmacy

The authors note they will continue to investigate treatments for patients with lupus as well as safe and effective methods of delivering these molecules to patients.

More cost effectiveness data is crucial in advocating for better insurance coverage in the United States.

Currently, limited data show the effect of adverse drug events in the outpatient setting.

Investigators compared the criteria for eligibility in the VICTORIA trial with guideline and label criterion, finding a wider than expected population with heart failure were eligible for vericiguat therapy.

Allison Burns discusses how pharmacists should prepare and educate themselves regarding OTC naloxone, and the steps that can be taken in stores and pharmacies to ensure OTC naloxone is visible and available.

On a scale from 1 to 10, respondents rated their feelings of burnout an average of 7.25 in the second annual Pharmacy Times Burnout and Mental Health Survey.

Switching from aflibercept (Eylea; Regeneron Pharmaceuticals) to biosimilar ranibizumab (Lucentis; Genentech) for neovascular age-related macular degeneration could be more cost effective for patients.

After failure with methotrexate, treatment with leflunomide is typically recommended, but treatment with biosimilars could have greater quality-adjusted life years.

Allison Burns, president and CEO of EMO Health, discusses the price point and stigma surrounding OTC naloxone in an interview with Pharmacy Times.

By embracing innovation in solid state cooling and proactively adapting to regulatory changes, pharmacies can improve patient access and compliance to medications, while taking advantage of additional revenue streams and proactively managing down costs.

In a new report, the FTC says pharmacy benefit managers act as middlemen in the pharmaceutical industry, leading to the squeezing of independent pharmacies and increases in prices for patients.

When initiated at a 15 mg dose and escalated to 30 mg, upadacitinib showed superiority compared with dupilumab, achieving Eczema Area and Severity Score (EASI) 90 at week 16.

By developing the Shizuoka score, which features a new predictive model using machine learning, patients with Kawasaki disease who are non-responders to intravenous immunoglobulin were able to be accurately identified.

In the 2 mg bulevirtide (Gilead Sciences) group, 44% of individuals achieved HDV RNA that was undetectable compared with 70% in the 10 mg group.

Investigators found improvements over the placebo in metabolic dysfunction-associated steatohepatitis without worsening fibrosis across 3 dosing groups.

Many patients who took technosphere insulin saw improvements in hemoglobin A1c, but other patients saw worsening with the drug.

The UK’s Medicine and Healthcare Products Regulatory Agency (MHRA) introduced changes to streamline its drug approval processes.

Jacqueline Bainbridge from the University of Colorado discussed what it meant to one of the recipients of the 2024 Giants of MS awards.

The CATALYST trial has identified hypercortisolism as a significant factor in approximately 1.2 to 1.3 million poorly controlled diabetes patients in the United States.

Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.

This is the first novel, precision mechanism of action to be released to treat patients with CIDP in over 3 decades.

RCT1100 is designed to deliver DNAI1 mRNA directly to affected airways through an inhaled nebulizer and fills an urgent unmet need in the treatment of those with primary ciliary dyskinesia.

This marks the first launch of a generic glucagon-like peptide 1 receptor agonist.

Staying updated on travel vaccines and applying sunscreen are examples of summer health counseling tips

Health professionals have expressed concerns regarding consistent naming standards, the regulatory process surrounding the approval of biosimilar drugs, and the lack of education they have about biosimilars.

The historical health data collected using wearable devices can now be used as secondary endpoints in trials, allowing researchers to monitor responses in real-time without invasive procedures.

After over 2 decades, the first inhaled product with a novel mechanism of action has been approved by the FDA for the treatment of chronic obtrusive pulmonary disorder.

Teplizumab (Tzield; Sanofi) has the potential to delay type 1 diabetes and the onset of stage 3 diabetes, but must be started in stage 1 of the disease.